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Abstract: The susceptibility of brain to secondary formation from lung cancer primaries is 
a well-known phenomenon. In contrast, the molecular basis for invasion and metastasis to 
the brain is largely unknown. In the present study, 31 brain metastases that originated from 
primary lung carcinomas were analyzed regarding over expression of Dishevelled-1 
(DVL1), Dishevelled-3 (DVL3), E-cadherin (CDH1) and beta-catenin (CTNNB1).  
Protein expressions and localizations were analyzed by immunohistochemistry. Genetic 
alterations of E-cadherin were tested by polymerase chain reaction (PCR)/loss of 
heterozygosity (LOH). Heteroduplex was used to investigate mutations in beta-catenin. 
DVL1 and DVL3 showed over expression in brain metastasis in 87.1% and 90.3% of 
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samples respectively. Nuclear staining was observed in 54.8% of cases for DVL1 and 
53.3% for DVL3. The main effector of the Wnt signaling, beta-catenin, was up-regulated 
in 56%, and transferred to the nucleus in 36% of metastases. When DVL1 and DVL3 were 
up-regulated the number of cases with nuclear beta-catenin significantly increased  
(p = 0.0001). Down-regulation of E-cadherin was observed in 80% of samples. Genetic 
analysis showed 36% of samples with LOH of the CDH1. In comparison to other lung 
cancer pathologies, the diagnoses adenocarcinoma and small cell lung cancer (SCLC) were 
significantly associated to CDH1 LOH (p = 0.001). Microsatellite instability was detected 
in one metastasis from adenocarcinoma. Exon 3 of beta-catenin was not targeted. Altered 
expression of Dishevelled-1, Dishevelled-3, E-cadherin and beta-catenin were present in brain 
metastases which indicates that Wnt signaling is important and may contribute to better 
understanding of genetic profile conditioning lung cancer metastasis to the brain. 
Keywords: Dishevelled-1 (DVL1); Dishevelled-3 (DVL3); E-cadherin (CDH1); beta-catenin 
(CTNNB1); brain metastases; lung cancer; immunostaining; loss of heterozygosity 
 
1. Introduction 
Metastasis is a highly selective process conditioned by the genetic profile of the original tumor as 
well as by organ environment. The susceptibility of the brain to secondary formation from lung cancer 
primaries is a well-known phenomenon. In contrast, the molecular basis for invasion and metastasis to 
the brain is largely unknown. Reports indicate that specific set of genes mediate metastasis to the brain 
according to discrete changes [1,2]. 
The work presented in this paper focused on the analysis of different expression levels of 
Dishevelled-1 (DVL1), Dishevelled-3 (DVL3), beta-catenin (CTNNB1) and E-cadherin (CDH1) in 
brain metastases that originated from primary lung carcinomas. All the molecules studied are key 
players in the classical Wnt signaling pathway which has today been established as one of the basic 
cellular pathways and whose misregulation plays an important role in tumorigenesis. Initiation of the 
Wnt signaling cascade depends on the presence of Wnts, glycoproteins that bind to receptors called 
frizzled. Thus, activated, the receptors recruit Dishevelleds at cytoplasmic membrane and this 
interaction also pulls axin from the beta-catenin destruction complex to the plasma membrane. In this 
fashion the complex is inactivated [3] leading to the stabilization of cytosolic beta-catenin. Stabilized  
beta-catenin enters the cell nucleus and associates with T-cell factor (TCF)/lymphoid enhancer factor 
(LEF) transcription factors, which leads to the transcription of Wnt-target genes such as c-myc, matrix 
metalloproteinase (MMP)7, cyclin D1, etc. [4–10]. In the absence of factors that activate Wnt signaling, the 
beta-catenin destruction complex that consists of adenomatous polyposis coli (APC)-Axin and glycogen 
synthase kinase 3 (GSK3) binds to beta-catenin with subsequent beta-catenin phosphorylation, 
ubiquitination, and degradation by proteasomes. In this scenario beta-catenin/TCF/LEF target genes are 
repressed [4,5,11]. However, mutations of the complex APC-Axin and GSK3 can also results in the 
translocation of beta-catenin to the nucleus ultimately leading to oncogenic transformation and progression. 
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The cellular function of human Dishevelled genes has not been completely elucidated yet.  
Nevertheless, Dishevelleds (DSH or DVL) are considered to be the central hub of Wnt signaling and 
are all multifunctional phosphoproteins that have been shown to shuttle between the cytoplasm and the 
nucleus [12–14]. The reported data on Dishevelleds’ role in tumorigenesis is controversial, although it has 
been demonstrated that they are over expressed in several types of cancers including lung cancer [15–19]. 
Of particular interest is a process very much involved in invasion and metastasis of tumors—the so 
called Epithelial-to-Mesenchymal Transition (EMT), where noninvasive tumor cells acquire motility 
and ultimately disseminate to places distant from the primary site. It has been shown that the Wnt 
signaling has a particularly tight link with EMT. For example, the nuclear translocation of beta-catenin 
can induce EMT [6,20,21] by activating the transcriptional repressors Snail and Slug that suppress  
E-cadherin expression [6,22–24]. Another important finding is that lymphoid enhancer factor 1 (LEF1) 
when over expressed leads to enhanced tumor invasiveness and induces EMT [2,20,25,26]. 
Besides being the main signaling effector molecule of the pathway, beta-catenin is also involved in 
the cellular architecture. It is bound to E-cadherin and is an essential component of adherens junctions.  
In this respect, it is important to remember that the most prominent feature of EMT is the destruction 
of adherens junctions and the loss of expression of the cell-cell adhesion molecule E-cadherin. 
Our hypothesis is that molecular components of the Wnt pathway, Dishevelleds, E-cadherin and 
beta-catenin, play important roles in metastasis of lung cancer to the brain. We believe that their 
altered levels of expression contribute to the outline of molecular profile of distant brain metastases. 
2. Results 
DVL1 and DVL3 showed over expression in brain metastasis tissues in 87.1% and 90.3% of 
samples respectively. The staining was observed mainly in the cytoplasm and was diffusely or 
granularly distributed. Nevertheless, we also observed nuclear staining of DVL1 in 54.8% of cases and 
DVL3 in 53.3% of cases. 
At the level of the complete brain metastasis sample, our analyses showed that there were 12.9% of 
samples demonstrating weak expression of DVL1; 45.2% moderate expression and 41.9% strong 
expression. Considering the expression levels of DVL3 in our total sample we observed 9.7% of 
samples with weak expression; 51.6% with moderate expression and 38.7% with strong expression. 
The normal levels of expression in healthy tissues were very weak. The expression levels of the two 
proteins in metastases, according to the starting points of the specific types of primary lung cancers are 
shown in Figure 1. For DVL1 the expression levels were not statistically different between the various 
pathological diagnoses (χ2 = 9.375; df = 8; p = 0.312). In contrast to this, the expression levels of 
DVL3 were statistically significantly different between the same pathological diagnoses (χ2 = 16.275; 
df = 8; p = 0.039). 
Normal levels of E-cadherin staining were scored as +++, and the protein was located along the  
cell membrane or inside the cytoplasm. The investigation on E-cadherin showed that overall 80% of 
metastases had down-regulation of E-cadherin. Intense down-regulation was noticed in 52% of cases. 
The majority of samples (88.9%) with E-cadherin’s gross deletions (LOH) were accompanied with 
down-regulation of E-cadherin protein. All metastases originated from small cell lung cancer (SCLC), 
adenocarcinoma and carcinosarcoma showed E-cadherin down-regulation, while in large cell carcinoma 
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and squamous cell carcinomas E-cadherin was down-regulated in 75% and 60% cases respectively. 
The expression levels of Dishevelleds were not associated to E-cadherin down-regulation (p = 0.856 
for DVL1; p = 0.310 for DVL3). 
Figure 1. The distribution of the expression levels of the two proteins in metastases 
according to the starting point of specific type of the primary lung cancer. (A) Dishevelled-1 
(DVL1); and (B) Dishevelled-3 (DVL3). 
 
Our next step was to detect whether the expression and cellular localization of beta-catenin, 
correlated with the expression levels of Dishevelleds and E-cadherin. We noticed that beta-catenin  
was up-regulated in 56%, and transferred to the nucleus in 36% of metastases. It is interesting to note 
that 40.9% of cases with up-regulated DVL1 expression had beta-catenin transferred to the nucleus. 
The percentage of metastases with up-regulated DVL3 that also exhibited nuclear staining of  
beta-catenin was 32%. When DVL1 was up-regulated the number of cases with nuclear beta-catenin 
significantly increased (McNemar test, p = 0.0001). The same trend was noticed when DVL3 was  
up-regulated (McNamar, test p = 0.0001). 
Approximately 25% of metastases showed simultaneous nuclear localization of Dishevelleds and 
beta-catenin. Statistical analysis showed a significant correlation between the nuclear localization of 
beta-catenin and DVL1 (p = 0.05), but no correlation between nuclear DVL3 and beta-catenin (p = 0.261). 
Only 4 primary lung cancers autologous to the brain metastases were available for the analysis. 
Three out of 4 primary lung cancers showed higher E-cadherin’s and lower beta-catenin’s expression 
levels than in the autologous brain metastases. All four primaries showed lower DVL1 expression levels 
when compared to the corresponding metastases, and 2 out of 4 primaries showed lower DVL3 levels. 
Detailed histopathological diagnosis, the origin of the lesions of metastasis sample and findings on 
the protein levels are presented in Table 1. Immunostaining of Dishevelleds 1 and 3 is demonstrated in 
Figure 2A–D and of beta-catenin protein in Figure 2E. Loss of E-cadherin’s expression is demonstrated 
in Figure 2F. 
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Table 1. The localization of the metastases, the polymorphic status for microsatellite markers used and genetic changes of the CDH1 gene, 
expression levels of E-cadherin, beta-catenin, DVL1 and DVL3 proteins, and pathohistological diagnosis of the primary site. 
Patient No. Location CDH1 D16S752&D16S265&D16S398 E-Cadherin Beta-Catenin Dishevelled-1 Dishevelled-3 Primary Tumor 
1 Cerebellum LOH D16S265 0 C++ N+ ++ +++ Large cell carcinoma 
2 Cerebellum HETERO +++ C++ ++ ++ Large cell carcinoma 
3 Frontal region HETERO ++ 0 + ++ Large cell carcinoma 
4 Parietal region HETERO +++ C+ +++ ++ Large cell carcinoma 
5 Occipital region HETERO + C++ ++ +++ Large cell carcinoma 
6 Frontal region HETERO + N++ ++ + Large cell carcinoma 
7 Occipital region HETERO ++ C+N+++ ++ ++ Large cell carcinoma 
8 Frontal region HETERO + C++ + ++ Large cell carcinoma 
9 Parietal region HETERO + C+ ++ ++ SCLC 
10 Frontal region LOH D16S398 0 C+ ++ ++ SCLC 
11 Parietal region LOH all 0 C++N+++ ++ ++ SCLC 
12 Parietooccipital region LOH D16S265 ++ C+ +++ ++ SCLC 
13 Parietal ND ND ND ++ ++ SCLC 
14 Parietal ND ND ND + + SCLC 
15 Cerebellum ND ND ND +++ ++ SCLC 
16 Cerebellum MSI D16S265 0 C+ +++ +++ Adenocarcinoma 
17 Temporal region HETERO + C+ ++ ++ Adenocarcinoma 
18 Parietal region LOH D16S752 ++ C+ +++ +++ Adenocarcinoma 
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Table 1. Cont. 
Patient No. Location CDH1 D16S752&D16S265&D16S398 E-Cadherin Beta-Catenin Dishevelled-1 Dishevelled-3 Primary Tumor 
19 
PR 
Frontal region 
ND 
LOH all 
+++ 
+++ 
C+++ 
C++N+ 
+ 
+++ 
++ 
++ 
Adenocarcinoma 
20 Temporal region LOH D16S398 ++ C+ ++ ++ Adenocarcinoma 
21 
PR 
Cerebellum 
ND 
LOH D16S752 
+++ 
+ 
0 
C+ 
++ 
+++ 
+ 
+++ 
Adenocarcinoma 
22 Temporal ND ND ND +++ + Adenocarcinoma 
23 Frontoparietal ND ND ND ++ ++ Adenocarcinoma 
24 Frontoparietal ND ND ND +++ ++ Adenocarcinoma 
25 Parietal region LOH D16S398 0 C++ + +++ Squamous cell carcinoma 
26 Parietal region HETERO +++ C+N++ +++ +++ Squamous cell carcinoma 
27 Parietal region HETERO +++ C+++ ++ +++ Squamous cell carcinoma 
28 Multiple metastases HETERO ++ C++N+ ++ +++ Squamous cell carcinoma 
29 Cerebellum HETERO + C+N++ +++ +++ Squamous cell carcinoma 
30 
PR 
Temporal region 
ND 
HETERO 
+++ 
+ 
C++ 
C+++N+ 
++ 
+++ 
+++ 
+++ 
Carcinosarcoma 
31 
PR 
Parietal region 
ND 
HETERO 
+++ 
+ 
0 
C+ 
+ 
+++ 
++ 
+++ 
Carcinosarcoma 
LOH = loss of heterozygosity; MSI = microsatellite instability; HETERO = heterozygous samples; HOMO = homozygous samples; ND = not determined; 0 = no expression; 
+ = weak expression; ++ = moderate expression; +++ = strong expression; C = cytoplasmic; N = nuclear localization; All = all three MS markers D16S752&D16S265&D16S398 
showing LOH; SCLC = small cell lung cancer; PR = denotes expression in the autologous primary lung cancer. 
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Figure 2. Brain metastasis samples immunohistochemically stained for the expression of 
DVL1, DVL3, E-cadherin and beta-catenin proteins. Strong expression of DVL1, (A) in 
cytoplasm; (B) in cytoplasm and nucleus; Strong expression of DVL3, (C) in cytoplasm;  
(D) in cytoplasm and nucleus; Nuclear expression of beta-catenin (E); and Loss of 
expression of E-cadherin protein (F). Original magnification, 400×; scale bar, 50 μm. 
 
The results of our genetic analysis indicate a total of 36% of the sample with LOH of the CDH1  
(E-cadherin) gene when assessed with 3 markers. The highest frequency of genetic changes was 
observed in metastases originating from primary sites with the diagnosis of lung adenocarcinoma and 
SCLC with 83.3% and 75% of changes, respectively, while squamous cell carcinoma (SCC) exhibited 
25%, and large cell carcinoma (LCC) 12.5% of LOHs. In comparison to other lung cancer pathologies, 
the diagnoses adenocarcinoma and SCLC were significantly associated to E-cadherin genetic changes 
with χ2 = 10.364; df = 1; p = 0.001. A type of genomic instability—microsatellite instability (MSI)  
was detected in one metastasis originated from adenocarcinoma. The results of heteroduplex analysis 
of exon 3 did not show samples with additional bands which indicated that mutational hot-spot of  
beta-catenin, was not targeted in our metastasis sample. 
3. Discussion 
Our results on DVL1, DVL3, beta-catenin and E-cadherin bring novel insights on the Wnt signaling 
role in brain metastases that originated from primary lung carcinomas. We investigated the combination 
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of Wnt key molecules in our collected tumor sample because Wnt signaling is involved in EMT  
and metastasis formation [27]. The results of investigations of DVL1 and DVL3 protein levels  
showed over expression in brain metastasis tissues in 87.1% and 90.3% of samples respectively.  
The involvement of DVL members in lung cancer is still very much unknown, particularly the 
association between changed expression and the pathohistological type of lung cancer from which  
the metastasis originated. Moreover, the correlation with tumor prognosis is still not established.  
Only several papers report the over expression of Dishevelleds in primary lung cancers.  
Uematsu et al. [18] report on DVL3 over expression in non-small cell lung cancer. They showed that 75% 
NSCLC tumors (¾ squamous and ¾ adeno) had DVL3 overexpression. They imply that these events, 
upstream of beta-catenin, are critical for activation of Wnt signaling. Surprisingly these authors did not 
detect expression of DVL1 or DVL2 which is different from our findings on the presence of DVL1 
over expression. 
Li et al. [28] discovered that DVL3 mRNA levels are significantly higher in pleural effusions from 
patients with adenocarcinoma and offered this finding as a marker for pleural micrometastasis. 
The findings that our investigation builds on are brought by Zhao et al. [16] and Wei et al. [29] who 
found that Dishevelled family proteins are over expressed in primary lung cancers. Zhao et al. [16] 
found positive expression of DVL1 and DVL3 in 45.1% and 48% of non small cell lung cancer (NSCLC) 
(squamous cell carcinoma (SCC) and adenocarcinoma). The expression levels of Dishevelleds were 
significantly higher in adenocarcinomas than squamous cell carcinomas. 
Wei et al. [29] showed that the positive expression rate in primary NSCLC tumors was 53.1% for 
total DVL, 36.3% for DVL1, 36.3% for DVL2 and 41.6% for DVL3. They also demonstrated that the 
positive expression rates of Dishevelleds were higher in tumor stages III and IV. Nodal metastases 
included in their study also showed higher expression levels of DVL1 and DVL3 than primary growths. 
Our findings on very elevated levels of Dishevelleds in brain metastases represent a logical continuation 
of the findings reported by these authors in primary lung carcinomas. Moreover, Wei et al.’s [29] data on 
the rise of Dishevelleds’ expression from primary (53.1%) to nodal metastases (87.2%) is additionally 
confirmed by our analysis that shows that 85.2% of Dishevelleds’ over expression is present when 
brain metastases are the final destination. 
So far it has been reported that DVLs are over expressed in various tumors types. The results from 
Nagahata et al. [15] suggest that amplification and up-regulation of the DVL1 gene are involved in 
breast carcinogenesis, especially in the acceleration of tumor growth. The involvement of DVLs in 
invasive ductal carcinoma of the breast was also reported by Prasad et al. [30]. Mizutani et al. [31] got 
similar results in prostate cancer. Their sample of 20 primary prostate cancer showed significant over 
expression of DVL1 (65%) and correlation to beta-catenin’s expression. Pulvirenti et al. [14] showed 
that DVL2 is over expressed in human high-grade gliomas. Results from Okino et al. [32] demonstrate 
increased expression of DVL1 in over two thirds of primary cervical squamous cell cancers when 
compared to corresponding non-cancerous uterine squamous cell tissues. All these data collectively 
indicate that amplification and increased expression of the DVL genes may play important role in the 
development of a portion of human cancers through derangement of the Wnt signaling pathway. 
Although reports indicate DVLs location in the nucleus is only sporadic [29], our study on brain 
metastases did not show this feature. We found nuclear staining of DVL1 proteins in 54.8% of cases 
and of DVL3 in 53.3%. It is known that DVLs interact with the wide range of protein partners in both 
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the cytoplasm and the nucleus [13]. Recently collected data [13,33–35] suggest that there are two 
cellular pools of DVLs: one that translocates to the nucleus, while the other remains in the cytoplasm. 
While it is not clear how it is regulated, when DVL is located in the nucleus it is known to interact 
with beta-catenin [13,36–38]. Our data support these findings by demonstrating that 25% of metastases 
simultaneously exhibit nuclear localization of Dishevelleds and beta-catenin. 
The majority of metastases had down-regulation of E-cadherin expression with intense down-regulation 
in 52% of cases. Similar results were reported by McDonald et al. [39] who also detected lower  
E-cadherin expression in metastatic lesions. Additionally, Saad et al. [40] demonstrated that loss of  
E-cadherin in patients with adenocarcinoma and squamous cell carcinoma (SCC) of the lung is 
significantly associated with increased risk of developing brain metastases. The results of other authors 
investigating E-cadherin in brain metastasis [41–43] collectively demonstrate that E-cadherin is 
constantly expressed in metastatic deposits. E-cadherin was expressed in the majority of our sample 
too, but contrary to the above studies, we observed different levels of its expression. E-cadherin’s 
expression in primary lung cancers is down-regulated in invasive component of 62% adenocarcinoma [44], 
and in another study in 72% of SCC and adenocarcinoma [45]. In 2 investigated cases of carcinosarcoma 
70% of cells showed E-cadherin’s down-regulation [46]. 
Recent studies [10] also show that DVLs are involved in tumor metastasis. Results from Shi et al. [47] 
indicate that specific protein domains shared by Dishevelleds and axin 1 (PDZ-RGS3 domains) enhance 
signals generated by Wnt canonical pathway which plays important role in EMT and tumor migration. 
Nuclear location of beta-catenin is an indicator of its acquisition of oncogenic activity. In our study, 
beta-catenin was up-regulated in 56%, and transferred to the nucleus in 36% of metastases. It is 
interesting to note that when DVL1 was up-regulated the number of cases with nuclear beta-catenin 
significantly increased (p = 0.0001). Additionally, when DVL3 was up-regulated, there was a significant 
number of cases with beta-catenin nuclear staining (p = 0.0001). A study by Guldur et al. [48]  
showed 66.7% of LCC samples, 53.4% of SCC and 42% of adenocarcinoma with positive beta-catenin 
staining, while all of their SCLC samples showed reduced beta-catenin staining. A study by  
Rodriguez-Salas et al. [49] showed cytoplasmic hyperexpression in 28% of SCLC and no nuclear  
beta-catenin staining. Only two samples were reported for carcinosarcoma staining of beta-catenin [46] 
and 70% of cells expressed beta-catenin with the strong intensity. 
In heteroduplex analysis, the conformational properties of the double stranded molecules are used to 
distinguish different base pairing (i.e., mutations). Annealing of mutant DNA to wild type probe gives 
duplexes with one or more mismatched bases (heteroduplexes). Mismatching causes the double helix 
to take on a conformation which retards its mobility during electrophoresis [50]. The results of our 
heteroduplex analysis did not demonstrate mutations of beta-catenin suggesting that mutations in  
exon 3 of the CTNNB1 gene are not associated to brain metastasis process. This finding is not unusual 
since many investigations [51–53] collectively demonstrated that mutation of APC, AXIN2 or  
beta-catenin are rarely seen in lung cancer [53,54] or are mutually exclusive, which is supported by our 
results. Uematsu et al. [19] also failed to detect mutations in exon 3 of beta-catenin in mesothelioma. 
Therefore nuclear beta-catenin accumulation may be a result of mechanisms other than mutation. 
Since there are no known mutations of beta-catenin in lung cancer it seems that alterations of the 
upstream effectors of beta-catenin’s degradation are responsible for the Wnt activation. The over 
expression of Dishevelleds act upstream of the destruction complex stealing axin from it and thus 
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disrupting it or preventing its proper formation. This event enables cytoplasmic accumulation of  
beta-catenin and its translocation to the nucleus which is also observed in our study. The underlying 
molecular mechanisms suggested by our study are that Dishevelleds over expression enhance 
transcriptional activity of beta-catenin. 
We are aware that our study was carried out on a relatively small number of brain metastases and, 
therefore, all conclusions made on this data set need to be tempered with caution. It is, however, 
important to note that despite the small number of cases analyzed, we recorded significant associations 
between DVL3 expression levels between the metastases originating from various primary tumors, 
upregulation of DVL1 and DVL3 and nuclear beta-catenin staining and also association of CDH1 
genetic changes and diagnoses adenocarcinoma and SCLC. What needs to be taken into account is the 
fact that the overall number of investigated cases reported in medical literature so far still remains 
shockingly small—after a comprehensive search of the available literature we found just 270 cases of lung 
cancer investigated for DVL1 and DVL3, and of these there was no data on potential brain metastasis. 
Although we are aware that it would be very interesting to draw comparisons between the primary 
lung cancer and the metastatic deposits, unfortunately it was not possible to attain the samples from the 
primary lung cancer except in 4 cases. Nevertheless, many authors performed analyses on primary 
lung cancer and report on the expression levels. Obviously, what needs to be done in the future is to 
analyze primary tumors and metastases in the same patient. 
Our previous investigations on brain metastases showed the involvement of yet another important 
component of Wnt signaling, the APC gene [55]. We found that 55% of metastases from lung 
carcinoma had LOH of this tumor suppressor gene. Three adenocarcinomas, 1 large cell carcinoma,  
1 small cell carcinoma, and 1 squamous cell carcinoma harbored gross deletions of APC gene. 
Although LOH of the APC gene is a common finding in lung cancer, point mutations of this tumor 
suppressor have not been frequent [54]. It is therefore interesting to report our finding of somatic 
mutation in exon 15 of the APC gene detected in one case of brain metastase derived from SCLC by 
direct DNA sequencing of the metastasis and autologous lymphocyte samples. The substitution was at 
position 5883 G–A in the metastasis tissue [56]. 
The biologic spectrum of metastases is unfortunately wide, heterogenic and difficult to predict, 
resulting in poor prognosis. Their proliferative activity and invasion are important characteristics that 
should be considered in diagnostics and prognosis. Why is the metastasis process from the lung so fast, 
particularly in comparison with the breast and the other primary locations? The velocity of metastasis 
establishment differs depending on the primary site and may therefore differ according to the genes 
involved. However, relevant information on the genes that are crucial in the metastatic process has not 
yet been utilized in diagnostics, prognostics, or therapeutic purposes. Novel findings point out the 
importance of chemokines and their receptors in brain metastasis formation [57]. Lung cancer is one of 
the most common malignancies and is the leading cause of cancer death in industrialized countries. 
Novel therapies aimed at inhibition of metastasis process based on better understanding of the biology 
of brain metastases will offer improvement in diagnosis and treatment of this disease. 
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4. Experimental Section 
4.1. Tumor Specimen 
Samples of 31 brain metastases from lung cancer, together with autologous blood samples were 
collected from the Department of Pathology and Department of Neurosurgery University Hospital 
“Sisters of Mercy”, Zagreb, Croatia. Using the magnetic resonance imaging (MRI) metastasis lesions 
were found in different cerebral regions, most frequently in parietal and frontal regions and 
cerebellum, with the surrounding zone of perifocal oedema. During the operative procedure the 
metastasis was maximally reduced using a microneurosurgical technique. The patients had no family 
history of brain tumors and did not receive radio- or chemotherapy before metastasis excision.  
All metastases were studied by pathologists and classified according to the WHO criteria [58]. There were 
8 large cell carcinoma (LCC), 7 small cell lung cancer (SCLC), 9 adenocarcinoma (AC), 5 squamous 
cell carcinoma (SCC) and 2 carcinosarcoma (CS) cases. The metastasis tissues for DNA extraction were 
frozen in liquid nitrogen and transported to the laboratory, where they were immediately transferred at 
−75 C. The peripheral blood samples were collected in EDTA and processed immediately.  
Twenty-two patients were male, and 9 were female. The age of patients varied from 46 to 81 (mean 
age 60.48, median 60 years). The mean age at diagnosis for males was 59.95, and for females 61.4 years. 
The local Ethical Committee approved our study, grant 1.2.1.19., and patients gave their  
informed consent. 
4.2. Immunohistochemistry 
Immunohistochemistry was performed in order to establish the levels of expression and cellular 
localization of Dishevelled-1, Dishevelled-3, beta-catenin and E-cadherin proteins. The samples were 
fixed in formalin, embedded in paraffin, sliced into 4-μm thick sections, and then fixed onto capillary 
gap microscope slides (DakoCytomation, Glostrup, Denmark). Sections were immunostained using 
streptavidin horseradish peroxidase/DAB (3,3'-diaminobenzidine) (Dako REAL™, EnVision™, 
Glostrup, Denmark). Briefly, sections were deparaffinized and rehydrated and then microwaved twice 
for 3 min at 700 W in citrate buffer and once for 4 min at 350 W to unmask epitopes. To block 
endogenous peroxidase activity, cells were fixed in methanol with 3% H2O2. Non-specific binding was 
blocked by incubating samples with goat serum for 30 min at 4 °C. Next, the primary antibodies were 
applied for 30 min at room temperature. The antibodies used for Dishevelled protein detection were: 
polyclonal rabbit anti-human DVL1 (diluted 1:50), Abcam, Cambridge, UK and monoclonal mouse 
anti-human DVL3 (diluted 1:50), Santa Cruz Biotehnology, Dallas, TX, USA. For E-cadherin protein 
detection monoclonal mouse anti-human E-cadherin NCH-38 (diluted 1:100), and for beta-catenin 
monoclonal mouse anti-human antibody (diluted 1:200), both Dako Corporation, Carpinteria, CA, 
USA, were used. 
Slides were then washed three times in phosphate-buffered saline (PBS)/goat serum, and secondary 
LINK antibody was applied for 1 h at 4 °C. Slides were again washed three times in PBS/goat serum and 
were incubated with substrate chromogen solution (EnVision™, Dako REAL™) for 30 s. 
Negative controls underwent the same staining procedure but without incubating samples with  
the primary antibodies. The frontal cortex of a normal brain, normal human placenta and normal 
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bronchial epithelia served as positive controls. Antibody labeling was analyzed by three independent 
and blinded observers using an Olympus BH-2 microscope. No expression or very weak expression 
was labeled as 0/+, moderate expression as ++, and strong expression as +++. Two hundred cells of 
each sample were analyzed. 
4.3. Genetic Analyses of E-Cadherin and Beta-Catenin 
For the genomic DNA extraction approximately 0.5 g of metastasis tissue was homogenized with  
1 mL extraction buffer (10 mM Tris–HCl, pH 8.0; 0.1 M EDTA, pH 8.0; 0.5% sodium dodecyl 
sulfate) and incubated with proteinase K (100 µg/mL; Sigma-Aldrich, St. Louis, MO, USA; overnight 
at 37 C). Phenol chloroform extraction and ethanol precipitation followed. Blood was used to  
extract leukocyte DNA. Five milliliter of blood was lysed with 7 mL distilled water and centrifuged  
(15 min/5000× g). The pellet was then processed as for DNA extraction from the tissue samples. 
4.3.1. Polymerase Chain Reaction (PCR) 
PCR amplification of microsatellite markers for the CDH1 (E-cadherin) gene was used to test loss 
of heterozygosity (LOH) in brain metastases. Allelic loss at the CDH1 locus was assessed using 3 highly 
polymorphic microsatellite markers—D16S265, D16S398 and D16S752, which map to 16q21–22.1 [59]. 
D16S265 and D16S398 are CA dinucleotide repeat polymorphisms and the D16S752 polymorphic 
region is a tetranucleotide GATA polymorphism (GATA51G03). All markers were amplified in a total 
volume of 25 µL, each primer 5 pmol, 200 ng DNA, 2.5 µL 10× buffer II, 1.5 mM MgCl2, 2.5 mM of 
each dNTP, 0.5 U Taq (Promega, Fitchburg, WI, USA). PCR conditions for D16S265, D16S398: 
initial denaturation 1 min/95 °C; denaturation, 30 s/95 °C; annealing, 1 min/55 °C; extension,  
30 s/72 °C; final extension, 72 °C/7 min; 30 cycles. PCR conditions for D16S752: initial denaturation  
3 min/96 °C; denaturation, 30 s/96 °C; annealing, 35 s/55 °C; extension, 30 + 1 s/72 °C; final 
extension, 72 °C/10 min; 30 cycles. 
Primers for D16S752: 5'-AATTGACGGTATATCTATCTGTCTG-3'; and 5'-GATTGGAGGAG 
GGTGATTCT-3'; for D16S265: 5'-CCAGACATGGCAGTCTCTA-3' and 5'-AGTCCTCTGTGCAC 
TTTGT-3'; and for D16S398: 5'-CTTGCTCTTTCTAAACTCCA-3' and 5'-GAAACCAAGTGGGT 
TAGGGTC-3'. 
PCR products were analyzed on 2% agarose gels, length of the D16S752 repeat was 102–126 bp, 
length of the D16S265 repeat was 89–117 bp, and length of the D16S398 repeat was 180–196 bp. 
4.3.2. Loss of Heterozygosity, Microsatellite Instability (MSI) 
Absence or significant decrease in the intensity of one polymorphic allele in metastasis compared to 
the heterozygous autologous blood sample was considered as LOH of CDH1 gene. The samples were 
electrophoresed on Spreadex gels EL 300 in the SEA 2000 submarine electrophoresis apparatus 
(Elchrom Scientific, Cham, Switzerland) at 120 V. Temperature of the running buffer was kept constant at  
55 °C. The samples were stained with SyberGold (Molecular Probes, Leiden, The Netherlands). All the 
PCR experiments were repeated twice and the LOHs were confirmed. The samples with LOHs were 
additionally electrophoresed on 15% polyacrylamide gels stained with silver. 
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MSI is a type of genomic instability indicating impaired cellular mismatch repair. Samples 
demonstrating MSI have bands on different positions in comparison to bands of autologous blood 
tissue due to a defect in the replication/repair machinery in tumor cells. 
4.3.3. Heteroduplex Analysis 
Exon 3 of the CTNNB1 (beta-catenin) gene was screened for mutations. Heteroduplexes were 
formed by heating 3 µL of PCR products (tumor mixed with normal DNA) at 95 °C for 3 min, 
followed by incubation on ice for 20 min. About 3 µL of each sample was mixed with 7 µL of mixture 
of formamide and 10 mM NaOH (1:100) prior to loading to a gel. The electrophoresis was performed 
on the GMA (Gene Mutation Analysis) gels in the SEA 2000 submarine electrophoresis apparatus 
(Elchrom scientific, Cham, Switzerland). The temperature of the running buffer was kept constant at 9 °C. 
4.4. Statistical Analysis 
All individuals were analyzed for the following features: pathohistological diagnosis (PHD) status, 
sex, age, CDH1 genetic changes, E-cadherin, Dishevelled 1, 3 and beta-catenin protein expression 
levels and localizations. Differences in the frequencies of the analyzed features were tested with the 
Pearson χ2 test employing Yates correction when appropriate and McNamar’s test. All statistical 
evaluations were performed using the SPSS statistical package, version 14.0 (SPSS Inc., Chicago,  
IL, USA). 
5. Conclusions 
Our findings suggest that altered expressions of Dishevelled-1, Dishevelled-3, E-cadherin and  
beta-catenin were present in brain metastases from lung cancer which indicates that Wnt signaling may 
be essential for the progression of lung cancer. 
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